Table 1. Ontological and functional associations of the canonical modules.
Each module is given with a representative hub gene, anatomic description, ontology and pathway, drug and disease associations.
| Module (Hub gene) | Anatomy | Ontology/Pathway (q-value FDR) | Drug/Disease (q-value FDR) |
|---|---|---|---|
| MO1 (GABRB3) | Telecephalon | Synaptic transmission, q<1.07e-17, regulation of synaptic pasticity, q<1.04e-10 (*) | Cocaine related disorders, q<4.51e-09, nicotene addiction, q<5.38e-06 (*) |
| M03 (KCNAB2) | Hippocampus, thalamus, pons, medulla | Neurotransmitter transport, q<4.28e-06 (*), axon part, 8.62e-07 (*) | Abnormality of pyramidal motor function, q<1.99e-03 |
| M04 (GABARAPL1) | Thalamocortical | Synaptic vesicle cycle, q<4.66e-14 (*), insulin receptor recycling, q<2.72e-05 (*) | Huntington’s Disease, q<1.28e-04 (*) |
| M06 (MEF2C) | Neocortex, claustrum | Postsynaptic membrane, q<2.5e-05, cell signaling, q<3.58e-06 | Clozapine (schizophrenia, bipolar disease), q<1.87e-03 |
| M07(NGEF) | Striatum, neocortex, amygdala | Calcium signaling pathway. q<1.07e-04, dendritic spine membrane, q<1.69e-03(*) | Fluxoxetine (depression, OCD), q< 4.34e-03 |
| M09 (PGAP1) | Hippocampus, amygdala, hypothalamus | Synaptic membrane, q<5.23e-04, zinc finger, CH-2, q<6.23e-03 | Cognitive impairment, q<5.99e-04, Amyotrophic lateral sclerosis, q<1.74e-03 (*) |
| M10 (ADORA2A) | Striatum | Monoamine GPCRs, q<7.27e-05 (*), dopamine receptor signaling, q<3.30e-05(*) | Drug induced dyskinesia, q< 1.23e-06 (*), haloperidol (schizophrenia, Tourette’s), q< 9.76e-07 |
| M11 (NTNG1) | Dorsal thalamus | Cadherin signaling pathway, q<2.02e-03 (*), cholinergic synapse, q<2.45e-04 (*) | Alzheimer disease-presenilin pathway, q< 2.78e-03 (*) |
| M12 (SLC6A3) | Substantia nigra, ventral tegmental area | Adrenaline, noradrenaline, q<5.48e-06, and dopamine biosynthesis, q<8.39e-06 (*) | Cocaine addiction, q <5.64e-05, dopamine, q<3.68e-06 |
| M14 (TLE6) | Hypothalamus | Neuropeptide signaling, q<9.75e-03 (*), GPCR ligand binding, q<1.76e-04 (*) | X-linked mental retardation, 2.47e-03 (*), Praeder-Willi syndrome, q< 2.47e-03 (*) |
| M15(NEFH) | Deep cerebellar nuclei, brainstem | Neuron projection, q<3.42e-03, neurofilament, q<3.49e-04 (*) | Dexamethasone(cerebral Inflamatory), q<4.99e-03 |
| M16 (SLC47A1) | Dentate gyrus | Protocadherin genes, q<5.740e-04 (*) | Depressive disorder, 8.48e-03(*), Parkinson’s, q<8.48e-03 |
| M17 (CBLN3) | Cerebellar cortex | Zinc fingers, C2H2-type, q<3.66e-05, spinal cord development, q<8.83e-03 (*) | |
| M19 (VDAC2) | Thalamus, cerebellar nuclei, brainstem | Vasculature development, q<1.17e-17 (*), mitochondrial, q<5.50e-82 | Ataxia, q<2.65e-09 (*), Leigh’s syndrome, q<2.18e-08 (*), Alzheimer’s disease, q<3.98e-22 (*) |
| M20 (B3GAT1) | White matter, neocortex, basal ganglia, ventral thalamus | Eukaryotic translation, q< 6.32e-03 (*), ribosomal nucleolus, q<4.82e-14 | Disease progression, q<5.79e-05, selenium, q<2.00e-06, Abnormal blood glucose, q<1.20e-03 (*) |
| M21 (GBP4) | Sensory-motor nuclei, choroid | Vasculature development, q<1.17e-17 (*) | Toluene (abuse), q<3.61e-15, losartan (stroke), q<8.13e-08, azidothymidine (HIV), q<1.17e-07 |
| M24 (POGZ) | Cerebellar cortex, dentate gyrus, white matter, basal ganglia | Zinc fingers, C2H2-type, q<7.37e-40, chromatin organization, q<2.77e-16 (*) | Beta-methylcholine, q<1.53e-16, ellipticine (cancer), q<1.32e-09 |
| M25 (RGS10) | Ependyma, white matter, substantia nigra | Immune system regulation, q< 3.71e-35 (*), inflamatory response, q<3.70e-26 (*) | Systemic lupus erythematosus, q < 8.49E-29 (*), Malignant glioblastoma, q<1.01e-9 |
| M26 (MYCBP) | Ependyma | Cilium organization, q<1.47e-28 (*), Axoneme,q<1.79e-33 (*) | Breathing disregulation, q < 2.25e-05 (*) |
| M28 (SERPINA6) | Interbrain-hindbrain nuclei | G-protein coupled receptors, q<4.06e-07 (*), olfactory receptors, q<1.0e-03 (*) | |
| M29 (GAS5) | White matter, substantia nigra, globus pallidus | Cytosolic ribosome, q<2.96e-102 (*), translation activity, q<1.81e-85 (*) | Influenza lifecyle, q<4.87E-69 (*), Vigabatrin (seizures, epilepsy), q<1.70e-18, |
| M30 (VAMP3) | White matter, ventral thalamus, globus pallidus | Myelination, neuron ensheathment, q<1.48e-06(*) | Cognitive impairment, q<8.99e-06 (*), Hereditory spastic parapaligia, q< 7.83 e-03 (*) |
| M32 (SLC25A18) | Striatum, amygdala, substantia nigra | Glial cell differentiation, q<4.04E-05, astrocyte differentiation, q<2.42e-04 (*) | Dexamethasone (corticosteriod), q<1.58e-07, deafness, q<6.67e-3(*) |
(*)
indicates uniquely associated with the module. Modules not reported are weakly annotated. All q-values 0.01 FDR.